Top line accelerating.
+3.1% YoY versus +0.6% prior. 3y CAGR +3.6%.
+3.1%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $15.0B
Live price unavailable
Fundamentals as of 2025-12-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
3 of 3 legendary models say BUY THC.
What would legendary investors pay for THC?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Mixed — Tenet Healthcare Corporation has 33.3% ROE but D/E 4.91.
Financial story
Mixed — Tenet Healthcare Corporation's 33.3% ROE is strong, but its 4.91 debt-to-equity is elevated.
Bottom line: THC is rated BUY by all 3 legendary models, 79% below avg fair value $895, but earns a B sector grade (60/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
THC's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
THC is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
3 of 3 legendary investor models rate THC a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $895. See the per-investor fair-value table in the valuation tab.
THC trades at 12.1x earnings. Sector context and per-investor signals are in the valuation tab.
THC and VTRS differ on P/E, ROE, and revenue growth. See the full THC vs VTRS compare matrix.
P/E 8.4x — 28% below the 5y median of 11.7x. Forward 9.1x signals EPS contraction next year.
8.4xHow does THC compare?
See exactly where THC ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingTHC sits at #17 in Healthcare with a B grade (60/100).